Lipoprotein(a) [Lp(a)] is an established genetically determined cardiovascular risk factor; however, comprehensive real-world data on its distribution and clinical significance in patients hospitalized with acute coronary syndromes (ACS) remain limited. We aimed to characterize Lp(a) concentrations in a contempor...
Michał Miszczak, Beata Mokrauz, P. Piwowarczyk et al.· BMC Cardiovascular Disorders· 0 citations
Elevated Lp(a) concentrations were independently associated with the angiographic extent of coronary artery disease in patients with acute coronary syndromes, including multivessel disease and chronic total occlusions, including multivessel disease and chronic total occlusions.
Michał Miszczak, Beata Mokrauz, P. Piwowarczyk et al.· Atherosclerosis Plus· 0 citations
Lp(a) may soon shift from a “silent threat” to a precise, actionable target in cardiovascular prevention, according to a review of the current evidence, which highlights gaps in knowledge, and discusses emerging therapeutic strategies.
Michał Miszczak, P. Piwowarczyk, G. Sobieszek et al.· Biomedicines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.